Introduction
Caspase-3 (also called CPP32 or apopain) [1] [2] [3] is a member of the cysteine protease family, which plays an important role in apoptosis. 4 Apoptotic signals activated by various stimuli converge towards a common pathway, in which caspases have a signaling role. More than 10 caspases have been identified in mammals. 5 Among them, caspase-3 has been implicated in cell death, based upon abnormalities found in knockout mice 6 and the inhibition of cell death by a caspase-3 inhibitor. 7, 8 Caspase-3 is synthesized as an inactive precursor of 32 kDa that is first processed into subunits (P20 and P12), and finally into active subunits (P17 and P12) when a death-inducing signal is applied. [1] [2] [3] Therefore, expression of caspase-3 precursor (pro-caspase-3) alone cannot induce apoptosis and its activation requires a death-inducing stimulus, such as cancer chemotherapy agents. 7 Several death-inducing genes have been reported to be useful for anticancer gene therapy, and some of them, including the thymidine kinase gene, require additional stimuli to kill cancer cells. Such regulation could have great advantages in cancer therapy, since targeting of additional stimuli could allow these genes selectively to kill transduced cells. In this context, the caspase-3 gene should be eminently suitable for anticancer gene therapy, because (1) it has a strong effect when activated, and (2) cell death is not induced by gene transduction alone.
As the gene delivery system we used a recombinant inactivated adenovirus vector 9, 10 with an expression cosmid consisting of the chicken ␤-actin promoter and the cytomegalovirus enhancer. 11 This method has the advantages of high transduction efficiency, loss of episomal adenoviral DNA after several cycles of cell proliferation without any effect on other foreign genes, and the ability to prepare high titer (Ͼ10 8 p.f.u./ml) viral stock solutions.
We previously showed that transduction of human caspase-3 gene into HeLa cells induced little apoptosis, whereas apoptosis was substantially induced by subsequent addition of anti-Fas antibody. 7 Accordingly, the present study investigated the effect of human caspase-3 gene transduction combined with exposure to chemotherapy using several cancer cell lines and a liver tumor model. Our results suggested the possibility of using the human caspase-3 gene for anticancer gene therapy.
Results
Effect of caspase-3 gene transduction on apoptosis in vitro To evaluate the effect of human caspase-3 (hcasp-3) and human caspase-1 (hcasp-1) gene transduction on apoptosis, HepG2 cells (a human hepatoma cell line) were transiently transduced with an hcasp-3-and hcasp-1-containing adenovirus vector ( Figure 1A ) or with the empty vector (as a control) together with a ␤-gal-containing adenovirus vector (as a reporter gene). As shown in Figure 1B (a-c) , almost all the HepG2 cells were positively stained with X-gal at 10 multiplicities of infection (MOI), indicating efficient expression of the transduced genes. There were some variations in the intensity of staining, possibly caused by differences in the number of copies of the transduced genes. The extent of apoptosis was estimated by TUNEL staining. As shown in Figure 1B (d-f) and C, the proportion of apoptotic cells rapidly increased to 80% on 1 day after transduction with 10 MOI of the hcasp-1 adenovirus, whereas transduction of hcasp-3 adenovirus or the vector alone induced a slight and no apoptosis after 3 days, respectively, findings consistent with previous observations. 7 Similar results were also obtained by assessing cells with nuclear fragmentation after staining using Hoechst33342 ( Figure 1B (g-i) and D). Furthermore, similar results were noted when HeLa cells (a human cervical carcinoma cell line) or AH130 cells (a rat hepatoma cell line) were used (data not shown). These findings indicated that hcasp-1 expression, but not hcasp-3 expression, could induce apoptosis by itself. The clinical application of hcasp-1 seemed to be difficult because it is not easy to regulate its apoptosis-inducing ability, so we focused on hcasp-3.
Efficient expression of hcasp-3 in an inactive form Since hcasp-3 transduction caused little apoptosis, inefficient expression of caspase-3 was a possibility. As shown in Figure 2 , however, expression of caspase-3 proform (P32) in hcasp-3-transduced cells was four-fold higher than in non-transduced or vector-transduced cells. We could not detect P20 (active P17 plus the prodomain), which is the product of caspase activation, in hcasp-3-transduced cells after culture for 3 days, indicating that hcasp-3 gene transduction alone did not cause caspase activation, a result that was consistent with the slight induction of apoptosis ( Figure 1 ). These findings indicated that hcasp-3 gene transduction using an adenovirus vector at 10 MOI resulted in efficient production of inactive caspase-3 and did not induce apoptosis.
Effect of etoposide on hcasp-3-transduced cells
Since caspase-3 activation requires a death-inducing stimulus, we added 100 m etoposide (a chemotherapy agent) to cultures from 1 day after adenovirus transduction. At this concentration, production of processed caspase-3 (P20) was observed in hcasp-3-transduced cells but not in vector-transduced cells ( Figure 3A ). The increase of pro-caspase-3 during etoposide treatment of hcasp-3-transduced cells may have been due to the sustained production of pro-caspase-3. Consistent with the results of caspase-3 activation, numerous hcasp-3-transduced cells, but few vector-transduced cells, underwent apoptosis after addition of etoposide to cultures as assessed by cell shrinkage ( Figure 3B ) and nuclear fragmentation ( Figure  3B and C). Similar results were also obtained when HeLa Effect of hcasp-3 transduction plus etoposide on Bcl-2-overexpressing AH130 tumors Bcl-2 is known as an anti-apoptotic protein, [12] [13] [14] and is reported to function upstream of caspase-3, 15,16 so we next examined the effect of hcasp-3 gene transduction on Bcl-2-overexpressing tumors. After injecting AH130-Bcl-2 cells, which constitutively overexpressed human Bcl-2, 17 into the livers of Donryu rats, Bcl-2-overexpressing AH-130 tumors were created. Then hcasp-3 or the vector was transduced. The level of caspase-3 expression in AH130 Bcl-2 tumors was equal to that in AH130 tumors as assessed by immunohistochemistry (Figures 4Aa, c  and 5Aa, c) , indicating that production of caspase-3 was not affected by the presence of Bcl-2. However, there was markedly less apoptosis of AH130 Bcl-2 tumors than AH130 tumors after administration of etoposide (Figures  4Ag and 5Ag) . Consistently, tumor volume increased when hcasp-3 was transduced into AH130 Bcl-2 tumors ( Figure 5B ). These results were also consistent with the previous observation that Bcl-2 inhibits caspase-3 activation in vitro, 15, 16 and indicated that hcasp-3 gene therapy would be less effective for Bcl-2-overexpressing tumors. Taken together, our findings suggested that hcasp-3 gene transduction using an adenovirus vector plus administration of etoposide may be effective for solid tumors, except for Bcl-2-overexpressing tumors. 
Figure 3 Induction of apoptosis by etoposide in hcasp-3-transduced, but not vector-transduced, HepG2 cells. (A) Activation of caspase-3 by etoposide in hcasp-3-transduced, but not vector-transduced, HepG2 cells. HepG2 cells were transduced with hcasp-3 (10 MOI) (hcasp-3) or the empty vector (10 MOI) (vector) together with the lacZ gene-containing adenovirus vector (10 MOI). One day after gene transduction, cells were treated with etoposide (100 m) for the indicated times, and were lysed. Expression of pro-caspase-3 (P32) and its active form (P20) was assessed by Western blotting using an anti-human caspase-3 antibody (Transduction Lab). 'no' means non-transduced HepG2 cells. Each sample contained 30 g of protein. Data are representative of three independent experiments. (B and C) Induction of apoptosis by etoposide in hcasp-3-transduced, but not vector-transduced, HepG2 cells. HepG2 cells were treated as described in (A), and were fixed and stained with X-gal buffer (X-gal) and Hoechst33342 (Hoechst) at the indicated times. Representative appearance of transduced HepG2 cells is shown in (B). The percentage of apoptotic cells was measured as nuclear fragmented cells per total cells after staining with Hoechst33342 at the indicated times (C). Data represent the mean ± s.d. (n = 4).

Figure 4 Effect of hcasp-3 transduction plus etoposide on AH130 tumors. (A) Induction of apoptosis by etoposide in hcasp-3-transduced, but not vectortransduced, AH130 tumors. AH130 tumors were directly transduced with hcasp-3 (hcasp-3) or the empty vector using adenovirus at 5 × 10 8 p.f.u. Four days after gene transduction, 0.2 mg/100 g body weight of etoposide (VP16(+)) or saline (VP16(−)) was injected. At 7 days after gene transduction, human caspase-3 expression (hcasp-3) and apoptosis (TUNEL) were assessed by immunohistochemistry and the TUNEL assay, respectively. (B) Reduction of tumor volume by etoposide treatment of hcasp-3-transduced, but not vector-transduced, AH130 tumors. AH130 tumors were treated as described in (A), and tumor volume was measured on the indicated days. hCasp-3 (circles) and the empty vector (squares) were transduced on day 0, and etoposide (open symbols) and saline (closed symbols) were injected on day 4. All data represent the mean ± s.d. (n = 7).
Discussion
We showed that the combination of hcasp-3 gene transduction and administration of etoposide could efficiently induce apoptosis in solid tumors and could reduce the tumor volume. Caspase-3 is a member of the cysteine protease family, 4 which is a crucial component of the machinery causing programmed cell death. 4, 18 Among the known mammalian caspases, we focused on caspase-3, because this seemed to be the most important caspase based on the observations that: (1) it is certainly involved in apoptosis; 6, 18 (2) it is expressed in many tissues; 1-3 and (3) it resembles Ced-3 (the C. elegans cell death gene) with regard to sequence homology and substrate specifity. We also considered that this gene has the advantages of a strong death effect and induction of typical apoptosis, which seemed to be important so as not to damage the surrounding normal tissues. Unlike caspase-1, the transduction of caspase-3 is itself insufficient to induce apoptosis (Figure 1 ), which is a great advantage for cancer gene therapy. This difference probably depends on the length of the N-terminal prodomain region, since caspase-1 possesses a long prodomain that allows oligomerization and self-activation through its prodomain, resulting in apoptosis, whereas caspase-3 possesses a short pro-domain and shows low self-activation ability. 19 Since hcasp-3 transduction alone did not induce apoptosis (Figures 1 and 4) , we used etoposide as a death-triggering factor. Etoposide targets DNA topoisomerase II and induces DNA damage, which triggers the machinery of apoptosis. In this mechanism, Bcl-2 family proteins act as signal regulators, and the caspases function as executors. When cells were exposed to a low concentration of etoposide, the apoptotic stimulus was weak and there was little caspase activation ( Figure 3A) , resulting in low levels of apoptosis ( Figure 3B and C) . In the case of caspase-3 transduction, there is a low level of initial activation subsequently caspase-3 activation shows self-amplification ( Figure 3A) , resulting in substantial induction of apoptosis ( Figure 3B and C) . Thus, etoposide plus caspase-3 transduction might show a synergistic effect. Triggering of caspase-3 activation is not restricted to etoposide, and various stimuli including other cancer chemotherapy agents, irradiation, and cytokines 4,5 should be effective. Anticancer therapy with hcasp-3 gene transduction has the following advantages: (1) radiationinsensitive or chemotherapy-insensitive tumors might become sensitive; and (2) induction of extensive apoptosis by a weak death signal which does not affect non-transduced cells. Accordingly, the dose of chemotherapy agents or radiation could possibly be reduced by using this gene, leading to effective cancer therapy with minimal side-effects.
The present study also revealed that a Bcl-2-overexpressing tumor showed resistance to apoptosis after hcasp-3 transduction and exposure to etoposide ( Figure  5 ). This result was consistent with our previous finding that Bcl-2 prevented apoptosis upstream of caspase-3 activation in cell lines. 16 Some tumors show considerable expression of Bcl-2, and caspase-3 gene transduction seems unlikely to be efficient for these tumors. However, since the extent of Bcl-2 expression varies, and the expression of other apoptosis-related proteins also differs, Bcl-2 expression will not always invalidate caspase-3 gene therapy. The ultimate efficacy may depend on the nature of the death-triggering agent and on the level of Bcl-2 expression.
In conclusion, our study raised the possibility of a new form of anticancer gene therapy by combining etoposide administration with hcasp-3 gene transduction using an adenovirus vector.
Materials and methods
Chemicals Anti-caspase-3 antibody was obtained from Transduction Lab (Lexington, KY, USA). Apoptag was from Oncor (Gaithersburg, MD, USA). Caspase-1 and caspase-3 cDNA was kindly provided by Drs J Yuan (Harvard Medical School, Boston) and VM Dixit (Genentech, Inc., South San Francisco), respectively. Other chemicals were purchased from Wako (Tokyo, Japan).
Cell lines
HepG2 cells 20 (a human hepatoma cell line) were maintained in RPMI 1640 medium supplemented with 2 mm l-glutamine, 1 mm sodium pyruvate, 0.1 mm non-essential amino acids, 10 mm Hepes/Na + (pH 7.4), 0.05 mm 2-mercaptoethanol, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% fetal calf serum (FCS). AH130 (a rat ascites hepatoma cell line) derivatives 17 (AH130-Bcl-2 and AH130-V cells with stable transduction of human bcl-2 or the empty vector, respectively) were maintained intraperitoneally in 200-250 g Donryu male rats (Japan SLC, Hamamatsu, Japan), according to our institutional guidelines. Expression of Bcl-2 protein was confirmed by Western blot analysis, as reported previously. 17 Recombinant adenovirus transduction and apoptosis assay Recombinant adenoviruses containing the human caspase-3 or caspase-1 gene (AxCAOYCaspase-3 and AxCAOYCaspase-1, respectively) and the lacZ gene (AxCAISLacZ) were constructed as described elsewhere. 9, 10 In brief, the expression cosmid cassette was introduced into the viral genome by homologous recombination, and the resultant virus was propagated using human embryo kidney 293 cells that stably expressed the proteins encoded by the E1 region. We purified the adenovirus by sequential centrifugation on double CsCl step gradients. The concentrated virus was dialyzed against phosphate-buffered saline with 10% glycerol. The titer of the virus stock solution was assessed by a plaque-forming assay using human embryo kidney 293 cells. A recombinant adenovirus that lacked any expression unit in the E1 deletion region (Adex1w1) was also prepared as a control.
HepG2 cells (2 × 10 5 cells) were transduced with caspase-3 or the empty vector using recombinant adenovirus at 10 MOI (p.f.u. per cells). At this dose transduction efficiency was almost 100% and transduction toxicity was weak. After incubation for 1 h at 37°C, cells were washed twice with phosphate buffer to remove free virions or liposomes. Transduced HepG2 cells were stained with Xgal, the TUNEL method, and Hoechst33342 at the indicated times, and apoptosis was measured as the percentage of TUNEL-positive or nuclear fragmented cells per total cells using fluorescence microscopy (Olympus BX50, Tokyo, Japan).
Western blotting
HepG2 cells were homogenized in buffer containing 50 mm Tris-Cl (pH 8.0), 20 mm EDTA, 1% SDS and 100 mm NaCl. The lysates were cleared by centrifugation, and caspase-3 precursor (P32) and its active form (P20; P17 + the prodomain) were detected by Western blot analysis using an anti-human caspase-3 antibody.
Liver tumor model AH130-vector cells or AH130-Bcl-2 cells (5 × 10 5 ) were injected into the livers of Donryu male rats to form solid tumors. Three days later, 5 × 10 8 p.f.u. of adenovirus was directly injected into the solid tumors. Four days after gene transduction, etoposide (0.2 mg/100 g body weight) was injected via the dorsal vein of the penis. At 0, 4 and 7 days after gene transduction, the rats were anesthetized for laparotomy and the tumors were measured using calipers. Almost all the tumors were globular and the volume was calculated by the equation V = ab 2 /2, where a is the longest diameter and b is the shortest diameter of the tumor. At 11 day after transduction, tumors were excised, fixed and embedded in paraffin. Expression of caspase-3 was detected by immunohistochemistry using an anti-human caspase-3 antibody. Apoptosis was assessed by TUNEL staining using ApopTaq (Oncor).
Statistical analysis
Statistical evaluation was performed by the paired t test or analysis of variance. Scheffe's test was used for individual comparisons of groups when a significant differ-ence was observed by analysis of variance. A P value of less than 0.01 was considered to indicate statistical significance.
